Luye Pharma Group Ltd.
LYPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6,061 | $6,143 | $5,982 | $5,200 |
| % Growth | -1.3% | 2.7% | 15% | – |
| Cost of Goods Sold | $2,017 | $1,939 | $1,841 | $1,803 |
| Gross Profit | $4,044 | $4,204 | $4,141 | $3,397 |
| % Margin | 66.7% | 68.4% | 69.2% | 65.3% |
| R&D Expenses | $499 | $586 | $857 | $683 |
| G&A Expenses | $582 | $644 | $583 | $571 |
| SG&A Expenses | $2,398 | $2,700 | $2,403 | $2,276 |
| Sales & Mktg Exp. | $1,816 | $2,056 | $1,820 | $1,705 |
| Other Operating Expenses | -$144 | -$111 | -$73 | $155 |
| Operating Expenses | $2,753 | $3,175 | $3,187 | $3,114 |
| Operating Income | $1,291 | $1,029 | $1,215 | $387 |
| % Margin | 21.3% | 16.7% | 20.3% | 7.4% |
| Other Income/Exp. Net | -$452 | -$329 | -$211 | -$513 |
| Pre-Tax Income | $839 | $700 | $670 | -$75 |
| Tax Expense | $194 | $161 | $86 | $70 |
| Net Income | $472 | $533 | $605 | -$145 |
| % Margin | 7.8% | 8.7% | 10.1% | -2.8% |
| EPS | 0.018 | 0.14 | 0.17 | -0.042 |
| % Growth | -87.5% | -17.6% | 504.8% | – |
| EPS Diluted | 0.018 | 0.14 | 0.17 | -0.042 |
| Weighted Avg Shares Out | 3,762 | 3,728 | 3,481 | 3,445 |
| Weighted Avg Shares Out Dil | 3,762 | 3,728 | 3,481 | 3,445 |
| Supplemental Information | – | – | – | – |
| Interest Income | $84 | $117 | $89 | $102 |
| Interest Expense | $562 | $675 | $472 | $399 |
| Depreciation & Amortization | $791 | $702 | $671 | $582 |
| EBITDA | $2,192 | $2,077 | $1,813 | $907 |
| % Margin | 36.2% | 33.8% | 30.3% | 17.4% |